Ocular Surface, published by Elsevier, stands at the forefront of ophthalmology research, with a notable Impact Factor reflecting its significant contribution to the field. As a vibrant platform for disseminating cutting-edge findings, this journal has achieved Q1 ranking in the Ophthalmology category as of 2023, placing it amongst the top-tier journals globally, specifically ranking 4th out of 137 in Scopus with an impressive 97th percentile. Spanning across the years from 2003 to 2024, Ocular Surface focuses on advancing knowledge in areas such as ocular pathology, therapy, and surgical interventions. While the journal is not open access, it provides invaluable insights and empirical data essential for researchers, professionals, and students dedicated to improving ocular health. With an address rooted in Amsterdam, Netherlands, this esteemed journal continues to enrich the global conversation in ophthalmology.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

PROGRESS IN RETINAL AND EYE RESEARCH, published by PERGAMON-ELSEVIER SCIENCE LTD, is a premier journal dedicated to the advancement of knowledge in the fields of ophthalmology and sensory systems. With an impressive impact factor and a Q1 category ranking in both Ophthalmology and Sensory Systems as of 2023, this journal exemplifies excellence in research dissemination. Given its stature, it ranks #1 out of 137 in Ophthalmology and #1 out of 42 in Neuroscience - Sensory Systems, placing it within the top percentile of scientific publications in these domains. The journal has been actively contributing to the field since its inception in 1994 and continues to be a vital resource for researchers, clinicians, and students seeking the latest insights and breakthroughs in the understanding of retinal diseases and eye health. While it maintains a traditional subscription model, the journal remains committed to publishing high-quality, peer-reviewed articles that drive forward the frontiers of eye research and therapeutic innovation. With its strong scientific rigor and a vast array of articles, PROGRESS IN RETINAL AND EYE RESEARCH is indispensable for anyone invested in the study of visual sciences.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

CORNEA is a prestigious peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the rapidly advancing field of ophthalmology with a particular emphasis on corneal research and diseases. With an impact factor categorized in the prestigious Q1 quartile for its discipline, CORNEA has established itself as a leading platform for the dissemination of both fundamental and clinical studies since its inception in 1982. The journal is ranked 25th out of 137 in the Scopus Medicine-Ophthalmology category, placing it in the 82nd percentile among its peers, which underscores its vital role in influencing ocular research and clinical practices. While the journal is not currently open access, it provides valuable insights and updates for professionals, researchers, and students working to advance knowledge in corneal health, contributing significantly to the ongoing dialogue in the ophthalmological community. With a commitment to excellence, CORNEA continues to publish high-quality research and reviews in its pursuit to improve ocular outcomes and patient care.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.